SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-18-002182
Filing Date
2018-02-09
Accepted
2018-02-09 17:31:16
Documents
6
Period of Report
2018-02-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K avir20180209_8k.htm 8-K 46472
2 EXHIBIT 10.1 ex_104828.htm EX-10.1 126119
3 EXHIBIT 99.1 ex_104818.htm EX-99.1 22144
4 ex_104828.jpg GRAPHIC 8305
5 aviragen_logo.jpg GRAPHIC 5881
6 vaxart.jpg GRAPHIC 4690
  Complete submission text file 0001437749-18-002182.txt   222646
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Filer) CIK: 0000072444 (see all company filings)

IRS No.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35285 | Film No.: 18593119
SIC: 2836 Biological Products, (No Diagnostic Substances)